Actively Recruiting

Age: 18Years +
All Genders
ID05211206

Association Between Peri-procedural Intravenous Hydration and Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis

Led by University of Calgary · Updated on 2026-04-29

13000

Participants Needed

1

Research Sites

25 weeks

Total Duration

On this page

Sponsors

U

University of Calgary

Lead Sponsor

M

McGill University

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are studying the relationship between the amount of intravenous fluids given around the time of endoscopic retrograde cholangiopancreatography (ERCP) and the risk of developing post-ERCP pancreatitis (PEP). ERCP is a procedure with a relatively high risk of adverse events, especially pancreatitis, which causes significant healthcare costs and patient burden. This study aims to understand whether the amount of fluid given during the procedure affects the chance of developing PEP. The study compares two groups of patients based on the volume of intravenous crystalloid fluids they receive immediately before, during, and after ERCP. One group receives aggressive hydration with 2 liters or more of fluid, while the other group receives conservative hydration with less than 1 liter. The study uses data from a previous multicenter prospective cohort to analyze these differences. Participants are adults referred for ERCP who can provide informed consent. Researchers will evaluate the occurrence of PEP within 30 days as the primary outcome. Additional information collected includes procedure details and other adverse events. Statistical methods will be used to assess the relationship between fluid volume and PEP risk. The study will monitor patients for 30 days after ERCP to measure outcomes and gather data on procedure success and adverse events.

CONDITIONS

Brief Title

IV Fluids and Post-ERCP Pancreatitis

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Subject referred for ERCP, regardless of indication
  • Subject age 18 years or older
  • Subject able to give informed consent to involvement be included
Not Eligible

You will not qualify if you...

  • Subject has a standard contraindication to ERCP
  • Subject or surrogate unable or unwilling to provide informed consent
  • Subject age < 18 years

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - Immediate pre-, peri-, and post-procedural period

Participants undergo endoscopic retrograde cholangiopancreatography (ERCP) during which intravenous fluids are administered and various clinical data are collected.

1 procedure visit (in-person)

Long-term Monitoring

Duration - Up to 30 days after ERCP

Participants are monitored for post-ERCP pancreatitis and other adverse events following the procedure.

Follow-up visits or assessments up to 30 days

Trial Site Locations

Total: 1 location

1

Peter Lougheed Hospital

Calgary, Alberta, Canada

Actively Recruiting

Loading map...

Research Team

N

Nauzer Forbes, MD MSc

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

Early Versus Late Laparoscopic Cholecystectomy After ERCP fo...

Laparoscopic Cholecystectomy

Actively Recruiting

1 location

Post-ERCP Pancreatitis Prophylactic Measures Implementation ...

Pancreatitis, Acute

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here